Piperacillin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Piperacillin.png | |
| Piperacillin
| |
| Systematic (IUPAC) name | |
| (2S,5R,6R)-6-{[(2R)-2-[(4-ethyl-2,3-dioxo-piperazine- 1-carbonyl)amino]-2-phenyl-acetyl]amino}-3,3-dimethyl- 7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H26N5O7S |
| Mol. mass | 516.548 g/mol |
| Pharmacokinetic data | |
| Bioavailability | not absorbed orally |
| Metabolism | largely not metabolised |
| Half life | 36–72 minutes |
| Excretion | 20% in bile, 80% unchanged in urine |
| Therapeutic considerations | |
| Pregnancy cat. |
B |
| Legal status | |
| Routes | IV, IM |
|
WikiDoc Resources for Piperacillin | |
|
Articles | |
|---|---|
|
Most recent articles on Piperacillin Most cited articles on Piperacillin | |
|
Media | |
|
Powerpoint slides on Piperacillin | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Piperacillin at Clinical Trials.gov Clinical Trials on Piperacillin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Piperacillin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Piperacillin Discussion groups on Piperacillin Patient Handouts on Piperacillin Directions to Hospitals Treating Piperacillin Risk calculators and risk factors for Piperacillin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Piperacillin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Piperacillin is an extended spectrum beta-lactam antibiotic of the ureidopenicillin class. It is normally used together with a beta-lactamase inhibitor such as tazobactam, which is commercially available as Tazocin or Zosyn. The combination has activity against many Gram-positive and Gram-negative pathogens and anaerobes, including Pseudomonas aeruginosa.
Piperacillin/tazobactam is administered intravenously. Its main uses are in intensive care medicine (pneumonia, peritonitis), some diabetes-related foot infections and empirical therapy in febrile neutropenia (e.g. after chemotherapy).
Dosing
Piperacillin is not absorbed orally, and must therefore be given by intravenous or intramuscular injection. The doses available differ slightly from country to country.
The doses listed here are adult doses. In the U.S., the dose is 3.375–4.5 g every 6 hours. In the UK, the usual dose is 4.5 g every 8 hours; but is licensed to be given as 2.25–4.5 g every 6–8 hours. The drug may also be given by continuous infusion, but this has not been shown to be superior.[1]
Trade names and preparations
Piperacillin alone:
- Pipracil (U.S. only)
Piperacillin/tazobactam:
- Tazocin (UK, marketed by Lederle)
- Tazocin (Japan, marketed by Toyama)
- Tazocin (New Zealand, marketed by Wyeth)
- Zosyn (U.S., marketed by Wyeth-Ayerst)
References
External links
- Zosyn (piperacillin/tazobactam combination) - information for U.S.
- Tazocin data sheet for New Zealand
Antibacterials for systemic use: beta-lactam antibiotics - penicillins (J01C) | |
|---|---|
| Antibiotics | Amoxicillin • Ampicillin • Azlocillin • Carbenicillin • Cloxacillin • Dicloxacillin • Flucloxacillin • Mezlocillin • Nafcillin • Piperacillin • Pivampicillin • Ticarcillin |
| Beta-lactamase inhibitors | Sulbactam • Tazobactam • Clavulanic acid |
| Combinations | Ampicillin/sulbactam (Sultamicillin) • Co-amoxiclav |
fi:Piperasilliini th:ปิปเปอราซิลลิน
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
